Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.
The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland.
Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and pediatric leukemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma. Our new vaccine is comprised of human antibodies fused with tumor-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumor cells."
Associate Professor Kristen Radford, Lead Researcher
Associate Professor Radford says the vaccine offers several key advantages over existing cancer vaccines, which have already shown promise in early clinical trials.
"First, it can be produced as an 'off the shelf' clinical-grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines," she said.
"Secondly, this prototype vaccine targets the key tumor cells required for the initiation of tumor-specific immune responses, thereby maximizing potential effectiveness of treatment, while minimizing potential side effects.
"We are very happy to see our research published in a prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future."
Pearson, F.E., et al. (2020) Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1‐specific CD8+ T cells. Clinical & Translational Immunology. doi.org/10.1002/cti2.1141.